RESEARCH + DEVELOPMENT

KPS develops, validates molecular diagnostic tests and provides molecular pathology services to detect predictive biomarkers in tumor samples for personalized targeted therapies

Why KPS?

  • In KPS you find special know-how in molecular pathology in combination with state-of-the art R&D infrastructure and internationally trained management. 

  • KPS is a fully independent private company, therefore intellectual property and confidentiality is most protected. 

  • In Hungary you find EU conform regulatory environment, western-style working moral at low cost, this is why Hungary is already a preferred clinical and translational research site of international pharma companies. In addition, state and EU provided applied research grants are also available.

Download our brochure (330kB, PDF)

Our genome sequencing lab is a part of the national r&d infrastructure network

Our genome sequencing laboratory and our Roche FLX Genome Sequencer FLX System was certified as a strategic research infrastructure by the National R&D Infrastructure Survey in this month. The Hungarian National R&D Infrastructure Survey launched as an alliance associate of the ESFRI (European Strategy Forum on Research Infrastructure) of the European Union.   ESFRI, the European Strategy Forum on Research Infrastructures, is a strategic instrument to develop the scientific integration of Europe and to strengthen its international outreach. The competitive and open access to high quality Research Infrastructures supports and benchmarks the quality of the activities of European scientists, and attracts the best researchers from around the world.   The mission of ESFRI is to support a coherent and strategy-led approach to policy-making on research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better use and development of research infrastructures, at EU and international level.   further information about ESFRI More»


Further news

Our publication has been released in Nature Reviews Drug Discovery

In July, Nature Reviews Drug Discovery will publish our CEO's paper about the chances of development of novel drug compounds and targeted therapy in the future. In the 1990s, the breast cancer drug trastuzumab (Herceptin; Genentech/Roche) More»

The benefit of science TODAY

The emergence of molecular-targeted medicine at the turn of the 21st century brought a breakthrough in the personalized treatment of tumors and inflammations, comparable only to the discovery of penicillin. At the turn of the nineteenth More»

Forum

Gyulladásos bélbetegségek Sziasztok,Ja igen, Tihany!Majdnem
2010, Június 24. 16:28 Csizkat

Gyulladásos bélbetegségek hmm, azert az rendjen van,
2010, Június 20. 21:39 Richard

Gyulladásos bélbetegségek Ezek olyan dolgok, hogy
2010, Június 14. 09:55 chysh